Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials

Table 4

Safety outcomes of NSAIDs included in this study.

Drug	Number of trials included	Total number of patients included	Number of events							Range of hepatotoxic events	Range of proportion; (×10^−2)
			AST > 3 ULN	ALT > 3 ULN	ALT, AST, or both > 3 ULN	ALP > 2 ULN	Hy’s Law	Liver-related discontinuation	Liver-related hospitalization
Celecoxib	4	789	—	2	—	—	—	—	1	1-2	0.13–0.38
Diclofenac	11	19998	395	864	19	—	3	492	4	3–864	0.015–4.3
Etoricoxib	1	17412	—	—	162	0	1	57	—	1–162	0.005–0.930

Remark. Hy’s Law: ALT > 3 ULN, and bilirubin ≥ 2 ULN; calculated from the minimal event and the maximal event due to the possibility of overlapping of patients.